The European Commission has backed the use of the companies’ adjuvanted VidPrevtyn Beta vaccine – which targets the Beta variant of SARS-CoV-2 – as a booster vaccine candidate on the back of two “immunobridging” trials comparing it with currently-approved jabs.
In those studies, VidPrevtyn Beta was found to trigger a higher production of antibodies against the Omicron BA.1 subvariant than Pfizer/BioNTech’s Comirnaty, and to restore immunity against multiple variants of the virus in people previously vaccinated with Comirnaty, Moderna’s Spikevax, and Janssen’s Jcovden.
